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Abstract
Background: People with vascular cognitive impairment (VCI) constitute a clinically heterogeneous group, but previous
symptomatic drug trials in VCI did not take this clinical heterogeneity into account. Executive dysfunction and memory impairment
are the cognitive domains that are most frequently impaired in VCI, and these impairments are likely to reflect vascular damage
to specific neurotransmitter systems, which opens the possibility for targeted symptomatic treatment directed at specific
neurotransmitters.
Objective: Here we describe the design of the “Symptomatic Treatment of Vascular Cognitive Impairment” (STREAM-VCI)
trial. In this proof-of-concept study, we investigate whether people with VCI with executive dysfunction due to vascular damage
to the monoaminergic neurotransmitter system differentially respond to a monoaminergic challenge, whereas people with VCI
with memory dysfunction associated with vascular damage to the cholinergic system will in turn respond to a cholinergic challenge.
Methods: The STREAM-VCI is a single center, double blind, three-way cross-over trial among 30 people with VCI, in which
subjects received a single dose of galantamine, methylphenidate, or placebo on separate occasions. The most important inclusion
criteria were a diagnosis of VCI with a Mini-Mental State Examination score of ≥16 and a Clinical Dementia Rating of 0.5-1.0.
For each person, the challenges consisted of a single 16 mg dose of galantamine, 10 mg of methylphenidate, and placebo, in
random order on three separate visits. Change in performance in executive functioning and memory was assessed directly after
the challenge using standardized neuropsychological tests. We will correlate a positive response to the cholinergic and
monoaminergic treatment with differences in structural and functional connectivity at baseline using structural magnetic resonance
imaging (MRI), diffusion tension MRI, and resting-state functional MRI.
Results: The protocol of this study is approved by the Medical Ethics Committee of VU University Medical Center and the
competent authority. The first participant was enrolled in April 2014. In September 2017, enrolment for the study was completed.
We expect to publish the results in 2018.
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Conclusions: STREAM-VCI is the first study to investigate the association of a response to a cholinergic and monoaminergic
treatment with structural and functional connectivity of the monoaminergic and/or cholinergic systems on MRI. We aim to predict
on an individual basis which individuals show a positive response to a cholinergic and/or monoaminergic challenge in people
with VCI. This may be instrumental in moving in the direction of individually-tailored pharmacological interventions based on
MRI measures in people with VCI.
Trial Registration: ClinicalTrials.gov NCT02098824; https://clinicaltrials.gov/ct2/show/NCT02098824 (Archived by WebCite
at http://www.webcitation.org/6xhO7Ya1q)
(JMIR Res Protoc 2018;7(3):e80)   doi:10.2196/resprot.9192
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Introduction
The two most prevalent cognitive symptoms in people with
vascular cognitive impairment (VCI) are executive dysfunction
and memory impairment [1,2]. However, the presence and extent
of these symptoms varies largely between people with VCI.
Previous intervention studies did not take this into account, and
until now, there is no approved symptomatic treatment for
people with VCI.
Recent insights in the neuropharmacological basis of cognitive
symptoms in VCI suggest that executive dysfunction is largely
related to dysfunction of the monoaminergic systems
(noradrenergic and dopaminergic) that project mainly from the
locus coeruleus. Memory impairment is thought to be related
to dysfunction of the cholinergic system projecting form the
nucleus basalis of Meynert [3-5]. Also, neuronal networks, such
as the default mode network (DMN), is assumed to be involved
in attention, concentration, and executive function. Vascular
damage is thought to cause impairment of the cholinergic and
monoaminergic neurotransmitter systems by damaging specific
white matter tracts and cause disturbances in the neuronal
networks such as the DMN [6-8], resulting in cholinergic and/or
monoaminergic deficits.
Galantamine is a drug that increases the availability of
acetylcholine in the synaptic cleft and previous studies have
shown positive results on memory in people with probable
Alzheimer’s disease [9-14]. Executive functioning might be
improved by increasing norepinephrine and dopamine
transmitters with methylphenidate. This drug can increase the
concentrations of dopamine and norepinephrine in the synaptic
cleft [15-17]. Two previous studies have shown a slight
improvement on cognition, based on Mini-Mental State
Examination (MMSE) scores, in people with dementia following
methylphenidate use [18,19].
Here we describe the design of the trial “Symptomatic Treatment
of Vascular Cognitive Impairment” (STREAM-VCI). In this
proof-of-concept study, we aim to study the individual change
on performance on executive function and/or memory function
after a single dose of methylphenidate and galantamine,
compared to placebo, in people with VCI. We will correlate the
change on performance after the pharmacological challenge
with functional and structural connectivity of the damaged
monoaminergic and cholinergic neurotransmitter systems using
a structural magnetic resonance imaging (MRI) and resting-state
functional magnetic resonance imaging (rs-fMRI) [20-24]. Based
on this information we aim to understand and predict which
individuals will benefit from a certain pharmacological
treatment. This could be a step forward towards personalized
drug treatment based on MRI measures.
Methods
Study Design
The STREAM-VCI is a single center, double-blind, three-way,
case cross-over pharmacological challenge study, in which
participants received a single dose of galantamine,
methylphenidate, or placebo on separate occasions. Participants
were primarily recruited from the Alzheimer Center of the VU
University Medical Center (VUmc). Also, subjects were
recruited after referral from the Department of Neurology of
the Utrecht University Medical Center (Utrecht) and the
outpatient clinic of the following hospitals: Groene Hart
Ziekenhuis (Gouda), Spaarne Gasthuis (Haarlem), and Tergooi
(Blaricum). Subjects were enrolled between April 2014 and
September 2017. The trial is registered at the clinical trial
register: NCT02098824.
Subjects
Subjects were people with VCI ranging from vascular mild
cognitive impairment to vascular dementia, according to the
definitions of the American Heart Association/American Stroke
Association [25]. Eligible people who satisfied the inclusion
and exclusion criteria were selected (Textbox 1). Individuals
fitting the inclusion and exclusion criteria were given the study
information and at least one week’s time to consider
participation in the study. The enrolment of 30 subjects was
complete in September 2017.
Randomization
Eligible subjects who fulfilled the inclusion and exclusion
criteria were given the study medication in a randomized order.
Latin squares balanced for first-order carry-over effects were
used, called Williams squares. Because of the uneven number
of treatments, a pair of squares was required to ensure balance
for first-order carry-over effects. Randomization was carried
out by an independent researcher. Medication was identified by
project and protocol number, packing number, expiration date,
storage requirement, and contents.
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Textbox 1. Inclusion and exclusion criteria for Symptomatic Treatment of Vascular Cognitive Impairment.
Inclusion criteria
• Outpatients
• Objective executive dysfunction and/or memory impairment on neuropsychological tests
• Imaging evidence of cerebrovascular disease (white matter changes (Fazekas ≥2), (lacunar) infarcts, and/or (micro)hemorrhages)
• Mini-Mental State Examination score of ≥16
• Clinical Dementia Rating of 0.5-1
• No contraindication for treatment with a cholinesterase inhibitor or methylphenidate
• Assessed by the treating neurologist as mentally capable of understanding the implications of study participation
• Presence of an informant/caregiver at the information visit and signing of informed consent
Exclusion Criteria
• Clinically-relevant history of abnormal physical or mental health interfering with the study as determined by medical history taking and physical
examinations obtained during the screening visit and/or at the study day as judged by the investigator
• Clinically-relevant abnormal laboratory results, electrocardiogram (ECG) and vital signs, or physical findings at screening and/or at the start of
the study day (as judged by the investigator)
• Unwilling or unable to stop smoking on the study day until the end of the study day
• Other causes that can explain cognitive symptoms including but not limited to: delirium, multiple sclerosis, amyotrophic lateral sclerosis,
progressive supranuclear palsy, mental retardation, infectious encephalitis that led to persistent cognitive deficits or head trauma with loss of
consciousness that led to persistent cognitive deficits
• Use of neuroleptics
• Use of celiprolol and sotalol
• Use of doses of corticosteroids that may interfere with the pharmacodynamic measurements performed in the study
• Use of Monoamine oxidase A/B inhibitors
• Current use of centrally acting anticholinergics
• Use of benzodiazepine within 48 hours before a study day
• Current use of a cholinesterase inhibitor
• Alcohol abuse (defined as use of alcohol despite significant areas of dysfunction, evidence of physical dependence, and/or related hardship due
to alcohol)
• Use of recreational drugs
• Concomitant use of inhibitors of CYP2D6 or of CYP3A4 (unless on a stable dose without any recent or upcoming changes)
• Any other condition that in the opinion of the investigator would complicate or compromise the study or the wellbeing of the subject
• Any contraindication for magnetic resonance imaging
Procedures
Prior to any study-related procedures, written informed consent
for the study was obtained from each subject. The study
consisted of a screening visit, followed by three study visits
(challenge phase). The screening visit occurred at approximately
1 to 6 weeks prior to the first study visit. After inclusion, the
study lasted a maximum of 9 weeks until the end of the third
study visit. Between each study visit, a wash-out period of at
least one week was scheduled. About 7 days after the end of
the third study visit, participants were contacted by telephone
to inquire about possible side effects. An overview of the study
can be seen in Figure 1.
Screening Visit
A full medical screening (medical history, physical examination,
vital signs in supine position, 12-lead electrocardiogram (ECG),
urinalysis and routine hematology, biochemistry and
electrolytes) was performed to assess a subject’s eligibility for
this study and to assess possible safety concerns of
administrating the study medication. Extensive information of
the medical screening can be found in Multimedia Appendix 1.
All participants were thoroughly trained and familiarized with
the central nervous system (CNS) tests on the screening visit
in order to minimize learning effects during the study. The tests
were performed in a quiet room with ambient illumination with
only 1 participant in the room per session. When a person met
the criteria for inclusion, an MRI was performed on the same
day. An overview of the screening visit can be seen in Table 1.
Study Visit
On each study visit, safety measures were performed prior to
drug administration, consisting of vital signs, 12-lead ECG and
urinalyses. Vital signs were checked again halfway through the
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visit and at the end of the occasion. During a study visit, 5
rounds of CNS tests were performed. Table 1 shows an overview
of the assessments during a study visit.
Intervention
During three separate study visits, subjects received a single
pharmacological challenge with galantamine, methylphenidate,
or placebo in a random order. The Department of Clinical
Pharmacology and Pharmacy of the VUmc manufactured
galantamine capsules, methylphenidate capsules, and its
matching placebo for oral use and guarded stability of the
products.
Galantamine
In this trial, a dose of 16 mg was administered (2 tablets of 8
mg). Galantamine is a reversible competitive inhibitor of
acetylcholinesterase and also has activity as an allosteric
modulator of nicotinic acetylcholine receptors [14]. In several
randomized, double-blind, placebo controlled clinical trials,
galantamine was effective in people with probable Alzheimer’s
disease [9-13]. The usual starting dose of galantamine treatment
is 8 mg per day [26]. In a previous study the dose was upgraded
to 16 mg per day to objectify a good clinical effect [27-29].
Adverse events of galantamine are particularly cholinergically
mediated events affecting the gastrointestinal system such as
nausea and vomiting which occur in >10% of the people [26].
Methylphenidate
Methylphenidate (MPH) is an indirectly working
sympathicomimetic drug with effects comparable to
amphetamines and a potent dopamine, norepinephrine, and
serotonin releaser that also inhibits the uptake of the released
biogenic amines into presynaptic neurons [15-17]. The dose of
MPH was chosen at 10 mg (2 tablets of 5 mg), taken orally.
This dose and administration of MPH was chosen based on
strategies used in previous trials in the elderly depressed,
open-label administration guidelines in the demented population
and because a preliminary study of MPH for apathy provided
data on the safety and efficacy of 10 mg of methylphenidate
administered two times a day [30]. The main adverse effects of
MPH are agitation, sleep problems, reduced appetite, and
palpitations. MPH is also associated with a modest rise in blood
pressure and heart rate [31].
Measures
Pharmacodynamic Assessments
A series of CNS tests were administered using the ‘NeuroCart’
to study the acute effects of the intervention on a set of the CNS
drug responsive domains (Table 2) [32].
Figure 1. Schedule diagram of the study. During the screening visit, a magnetic resonance imaging (MRI) is performed. After randomization, a person
is placed in one of the 6 study arms. One week after the last study visit, follow-up by telephone will take place. Between each study visit, a wash-out
period of one week is scheduled.
JMIR Res Protoc 2018 | vol. 7 | iss. 3 | e80 | p.4http://www.researchprotocols.org/2018/3/e80/
(page number not for citation purposes)
Leijenaar et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Table 1. Overview of the screening and the study visits. On the study days, the pharmacological challenge is administered at time point 0.
Study visits (1, 2, 3) with time points (hours)Screening visitAssessments
3.53.02.52.01.51.00-1.5
Clinical measures
XbClinical proceduresa
XXXXVital signs
XX12-lead electrocardiogram
XXUrinalysis
XClinical laboratoryc
XXXXPharmacokinetics blood sampling
XDrug administration
Central nervous system tests
XXXXXEye movements
XXXXXAdaptive tracker
XXXXXVisual Analog Scales
XXXXPharmaco-electroencephalography
XXXXVisual Verbal Learning Test-15
XXFacial recognition task
XXXXXN-back task
XXXXXStop Signal test
XMagnetic resonance imaging
aClinical procedures include medical history and medication use, Mini-Mental State Examination, Clinical Dementia Rating scale, and physical
examination.
bX: the assessment was performed.
cClinical laboratory includes hematology and blood biochemistry.
Table 2. Functions measured by each task.
FunctionTask
Subjective Drug EffectsVigilancePsychomotor speedMemoryExecutive Functioning
XXaN-back task
XStop Signal Task
XXXAdaptive tracking
XVisual Verbal Learning Test–15
XFacial encoding
and recognition task
XEye movements
XPharmaco-electroencephalography
XBond and Lader Visual Analog Scale
aX: task belongs to the function in the column.
Executive functioning was measured by the tasks adaptive
tracking [33-35], Stop Signal Task [36,37], and N-back task
[38-40]. Memory was assessed by Visual Verbal Learning
Test-15 (VVLT-15) [41], N-back task and the Facial Encoding
and Recognition Task [38,42]. The VVLT-15 contains 3
different subtests. The immediate word recall test was performed
first; after an interval of approximately 60 minutes, the delayed
word recall test and then the delayed word recognition test were
performed. Our main outcome is defined as the change in
performance after a pharmacological challenge on the VVLT-15
and the adaptive tracker.
Besides executive functioning and memory the following
functions were measured: psychomotor speed, vigilance, and
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subjective drug effects. The following Neurocart tests were used
for the measurement of these functions: saccadic and smooth
pursuit eye movements [33,34], adaptive tracking, and Bond
and Lader Visual Analog Scale [43,44]. In Table 2, the tests
with corresponding cognitive functions can be seen.
MRI measurements
The MRI was acquired on 3T whole-body MR system
(Discovery; GE Medical Systems Milwaukee, WI, USA), using
an eight-channel head coil at the VUmc. The following
sequences were applied: T1-weighted imaging, T2-weighted
imaging, fluid-attenuated inversion recovery (FLAIR), Diffusion
Tensor Imaging (DTI) MRI and resting-state functional MRI
(rs-fMRI). In total, the imaging took about 40 minutes. There
was no intravenous contrast administration. All scans were
checked by a neuroradiologist for unexpected gross
abnormalities.
Medial temporal lobe atrophy was rated on the coronal
reconstructions of the T1-weighted images with scores ranging
from 0-4 [45]. Posterior atrophy was rated on the combination
of T1-weighted and FLAIR sequences and global cortical
atrophy was rated on FLAIR sequences using a 4-point visual
rating scale (0–3) [46-48].
White matter hyperintensities (WMH) were rated using the
Fazekas scale, with scores ranging from 0-3, on the FLAIR
images [49]. Microbleeds were defined as small round
hypointense foci on T2*-weighted images, with a maximum
diameter of 10 mm located in brain parenchyma. Lacunes were
defined as deep lesions (3-15 mm) with cerebral spinal
fluid—like signal on all sequences. A rater who was blinded
for all clinical information assessed the scores.
We are currently preprocessing all images. They will be
normalized to standard Montreal Neurological Institute (MNI)
space with FSL software [50,51]. Presence and location of
lacunar infarcts in each subject will be assessed and the severity
and location of WMH will also be measured using automated
segmentation [52]. Structural connectivity will be assessed using
DTI “fiber tracking” with FSL software. We will segment
specific white matter tracts part of the cholinergic and
monoaminergic systems, by means of probabilistic tractography.
Diffusion properties (fractional anisotropy and mean diffusivity)
will be investigated along the tract pathways. Functional
connectivity will be assessed using rs-fMRI. Individual
connectivity maps will be identified using standard resting state
network maps from FSL. These maps include eight resting state
networks, including the DMN and executive control network.
Pharmacokinetic assessments
Blood samples (4mL) for plasma concentrations of galantamine
and methylphenidate were collected repeatedly. According to
protocol, blood samples were taken before administration of
the medication and 1 hour, 2.5 hours and 3.5 hours after
administration (Table 1). The exact dates and times of blood
sampling were recorded. Samples were centrifuged at 2000G
during 5 minutes at 4 degrees Celsius. Plasma was transferred
into 2 mL Sarstedt tubes by pipette. The plasma was stored at
-20 degrees Celsius for the most optimal stability until analyses.
For the analysis of galantamine and methylphenidate, two
dedicated liquid chromatography—mass spectrometry / mass
spectrometry methods were developed. Each method was
specific and sensitive for the analysis of interest. Bioanalysis
was performed by the Pharmacy at the VUmc, Amsterdam.
ADAPT II Release 4 software was used [53]. Pharmacokinetic
parameters will be estimated using compartmental analysis.
Statistical analyses
Sample size
Based on a recently performed study at the Centre for Human
Drug Research in people with Alzheimer’s disease, acute effects
of galantamine on Neurocart tests have been measured
(CHDR0915). In this study, the difference in adaptive tracking
performance between galantamine and placebo occasions was
2.07% with a standard deviation of 3.35. Assuming that a
comparable efficacy can be seen in people with VCI and
monoaminergic neuronal dysfunction supplemented with
methylphenidate, and assuming a similar standard deviation,
we would need at least 24 subjects with VCI to show a mean
difference of approximately 2.0% (on adaptive tracker) with a
power of 80%. For the galantamine challenge, the VVLT-15
was used to calculate the sample size. In this study, the
difference in VVLT-15 between galantamine and placebo was
3 words with a standard deviation of 3.0. Assuming that in
people with VCI and cholinergic neuronal dysfunction
supplemented with galantamine, a 2-word difference should be
possible, and assuming a similar standard deviation, we would
need at least 24 people with VCI. Taking into account a 25%
drop out rate, we enrolled 30 subjects.
Planned analyses: Pharmacodynamics
The main outcome of this study is the individual change on the
CNS tests after a pharmacological challenge. Participants will
be categorized as a responder or nonresponder (defined as a
significant difference on Neurocart tests) on both active
conditions. Statistical analyses of outcome measures will be
performed by using mixed-model analyses of variance
(ANOVA) with treatment, period, time, and treatment by time
as fixed factors; participant, participant by treatment, and
participant by time as random factors; and the average baseline
measurement as covariate for each test on each time point.
Single-measured parameters without pre-value measurement
will be analyzed with a mixed-model ANOVA with treatment
and period as fixed factors and subject as random factor. The
Kenward-Roger approximation will be used to estimate
denominator degrees of freedom and model parameters will be
estimated using the restricted maximum likelihood method. The
general treatment effect and specific contrasts are reported with
the estimated difference and the 95% confidence interval, the
least square mean estimates, and the P value. For repeated
measures, graphs of the Least Squares Means estimates over
time by treatment will be presented with 95% confidence
intervals as error bars, as well as change from baseline Least
Square Means estimates. All statistical hypothesis tests are
conducted at alpha=0.05 (two-sided). No adjustments for
multiple comparisons will be applied.
Furthermore, we will correlate the location and severity of the
cerebrovascular lesions to the derived white matter fiber tracts
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and neuronal networks. ANOVAs adjusted for age, sex, and
baseline cognition will be performed to associate MRI measures
for structural and functional connectivity with a positive
response to the cholinergic and to monoaminergic challenge.
Subsequently, we will use logistic regression to identify the
most optimal combination of MRI measures to predict response.
Planned Analyses: Pharmacokinetics
Where appropriate and possible, the relationship between plasma
concentrations of galantamine/methylphenidate and a
corresponding selection of relevant pharmacodynamic
measurements will be defined and the data will be plotted to
evaluate the relationship graphically. If deemed appropriate and
possible, a suitable pharmacokinetic/pharmacodynamic model
may be applied to describe the exposure/concentration-effect
relationship.
Ethical Considerations
The protocol of this study was approved by the Medical Ethics
Committee of VU University Medical Center (protocol number
2013.393) and the competent authority (number
NL45933.029.13). The trial is registered at the European Union
Clinical Trials Register (2013-003396-35). The study was
conducted according to the Dutch Act on Medical Research
involving Human Subjects. An independent monitor (quality
manager) of the Centre of Human Drug Research monitored
the study data according to Good Clinical Practice.
All adverse events reported spontaneously by the subject or
observed by the investigator or his/her staff were recorded. The
occurrence of an adverse experience that was fatal,
life-threatening, disabling, required or prolonged in-patient
hospitalization, or caused congenital anomaly was described as
a serious adverse event (SAE). A Suspected Unexpected Serious
Adverse Reaction (SUSAR) was defined as an unexpected
serious adverse reaction in subjects given a drug that may or
may not have been dose related, but was unexpected, as they
were not consistent with current information.
Results
The first participant was enrolled in March 2014. Participant
enrolment was completed in September 2017. After
data-cleaning and locking of the database, we will start analyzing
the results. We expect to publish the results in 2018. No SAEs
or SUSARs have occurred during the study.
Discussion
The STREAM-VCI is a double-blind, three-way, case cross-over
trial, in which people with VCI received methylphenidate,
galantamine, or placebo in a random order. With this trial, we
aim to improve executive function and memory in people with
VCI using pharmacological interventions aimed at the
enhancement of monoaminergic and cholinergic
neurotransmitter systems.
VCI is one of the most important subtypes of cognitive
impairment [1,2,54,55], and as of date, there is no approved
symptomatic treatment for people with VCI. Evidence suggests
that executive dysfunction and memory complaints in VCI are
caused by damage to monoaminergic and cholinergic
neurotransmitter systems, respectively [8,20-24]. In the past,
several studies have investigated the effect of pharmacological
intervention with methylphenidate and a cholinesterase inhibiter.
However, the results of these studies were contradictive with
some studies showing a positive effect of the intervention and
other studies showing no effect [16,19,56]. A possible
explanation for the lack of conclusive results may be the
heterogeneity in symptoms displayed by people with VCI.
Previous studies did not take this interpatient variability into
account. By using structural and functional connectivity
measures of the cholinergic and monoaminergic tracts, we aim
to visualize how vascular damage affect these tracts in each
person. By doing so, we aim to understand why some people
respond to the challenge and some people do not. In this
proof-of-concept study, we expect that people with VCI with
executive dysfunction due to vascular damage to the
monoaminergic neurotransmitter system will respond to a
monoaminergic challenge and that people with VCI with
memory dysfunction caused by vascular damage to the
cholinergic system will have a positive response to a cholinergic
challenge.
STREAM-VCI is the first study to take the heterogeneity of
people with VCI into account by correlating the cognitive
symptoms with structural and functional connectivity in
monoaminergic and cholinergic systems measured with
structural and functional MRI and by correlating these changes
with a positive response to a challenge with galantamine or
methylphenidate. Based on this information, we aim to develop
a prediction model that estimates a positive response to a
cholinergic and/or monoaminergic challenge in people with
VCI. This could be a major step forward towards
individually-tailored pharmacological interventions aimed at
the affected neurotransmitter systems.
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Abbreviations
ANOVA: analyses of variance 
CNS: central nervous system
DMN: default mode network 
DTI: Diffusion Tensor Imaging 
ECG: electrocardiogram 
FLAIR: fluid-attenuated inversion recovery 
MMSE: Mini-Mental State Examination
MNI: Montreal Neurological Institute 
MPH: Methylphenidate  
MRI: magnetic resonance imaging 
rs-fMRI: resting-state functional magnetic resonance imaging
SAE: serious adverse event
STREAM-VCI: Symptomatic Treatment of Vascular Cognitive Impairment
SUSAR: Suspected Unexpected Serious Adverse Reaction 
VCI: vascular cognitive impairment 
VUmc: VU University Medical Center 
VVLT-15: Visual Verbal Learning Test-15 
WMH: white matter hyperintensities 
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